Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 23, 2022
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
[ Wed, Mar 23rd 2022
] - WOPRAI
Tue, March 22, 2022
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
[ Tue, Mar 22nd 2022
] - WOPRAI
Paul Choi Maintained (URGN) at Hold with Increased Target to $11 on, Mar 22nd, 2022
Paul Choi of Goldman Sachs, Maintained "UroGen Pharma Ltd." (URGN) at Hold with Increased Target from $10 to $11 on, Mar 22nd, 2022.
Paul has made no other calls on URGN in the last 4 months.
There is 1 other peer that has a rating on URGN. Out of the 1 peers that are also analyzing URGN, 0 agree with Paul's Rating of Hold.
This is the rating of the analyst that currently disagrees with Paul
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $34 on, Tuesday, January 18th, 2022
